Develops drugs for inflammatory diseases.
Dec 2025Revenue €1.11B/yrExpenses €817M/yr
No trend
Figures by year
Is Lakefront Biotherapeutics profitable?
Yes. In the 12 months to Dec 2025, revenue was €1.11B and expenses €817M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | €1.11B | €817M | €295M |
| Dec 2024 | €276M | €464M | −€188M |
| Dec 2023 | €240M | €328M | −€88.3M |
| Dec 2022 | €241M | €372M | −€131M |
| Dec 2021 | €234M | €406M | −€172M |
| Dec 2020 | €478M | €657M | −€179M |
| Dec 2019 | €835M | €466M | €369M |
| Dec 2018 | €279M | €326M | −€47.1M |
| Dec 2017 | €127M | €217M | −€89.8M |
| Dec 2016 | €130M | €141M | −€11.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.